Profound Medical Corp
PROF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$271.98M
Close$
$-4.77
164.1% downside
Current Fair Value
164.1% downsideOvervalued by 164.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $271.98 Million |
|---|---|
| Enterprise Value | $238.74 Million |
| Earnings per Share | $-1.43 |
| Beta | 0.53 |
| Outstanding Shares | 36,556,064 |
Return
| Return on Equity | 164.32% |
|---|---|
| Return on Assets | 131.19% |
| Return on Invested Capital | -49.88% |
Valuation & Multiples
| P/E Ratio | -7.4 |
|---|---|
| PEG | 18.88 |
| Price to Sales | - |
| Price to Book Ratio | 7.44 |
| Enterprise Value to Revenue | 28.03 |
| Enterprise Value to EBIT | -8.98 |
| Enterprise Value to Net Income | 2 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Last Earnings Call
Report Date
November 12, 2026
EPS Estimate
-$0.23
Consensus analyst estimateRevenue Estimate
$6.78 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 4, 2027
EPS Estimate
-$0.26
Consensus analyst estimateRevenue Estimate
$7.66 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 226.30% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 12.09%▼ 32.10% |
|---|---|
| Total Invested | $25.24M▼ 76.15% |
| Investors Holding | 13▼ 48.00% |
About Profound Medical Corp
162 employees
CEO: Arun Swarup Menawat
Profound is a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Profound is commercializing TULSA-PRO®, a technology that combines real-time MR...